Maintenance hormone therapy after ovarian cancer responds
Treatments studied
Part of Cancer, Digestive system, Women’s health & pregnancy clinical trials.
This Phase 3 trial tests whether ongoing treatment with an aromatase inhibitor (a hormone-blocking medicine) after initial chemotherapy can help keep epithelial ovarian/fallopian tube/peritoneal cancer from coming back. It is only for certain tumor types that are hormone-receptor positive (ER+).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have newly diagnosed epithelial ovarian, fallopian tube, or peritoneal cancer at FIGO stage II to IV
- Have had surgery to remove tumor (interval-debulking is allowed) and be able to do normal daily activities (ECOG 0–2)
- Have had at least 4 cycles of platinum chemotherapy in total (neoadjuvant chemotherapy is allowed)
- Your tumor must test positive for ER (estrogen receptor) at the trial’s lab (at least 1%)
- Be able and willing to attend study visits and follow study procedures, including taking tablets
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized cancer therapy designed just for you and your tumor. It is for people with newly diagnosed advanced ovarian cancer who can wait a short time before starting treatment and plan to have surgery after 2 cycles of chemotherapy.
This study tests a new maintenance therapy for people with advanced ovarian cancer that has responded well to initial chemotherapy. The goal is to see if it helps keep the cancer from coming back.
This Phase 2 trial tests giving chemotherapy before surgery, then continuing two medicines afterward (olaparib and pembrolizumab). It’s designed for people with newly diagnosed Stage III/IV ovarian, fallopian tube, or primary peritoneal cancer who may benefit from tighter control of the disease.
This study tests whether letrozole, a hormone-blocking medicine, can help people with newly diagnosed low-grade serous ovarian cancer that has hormone receptor proteins (ER and/or PgR) after surgery. It compares outcomes to see if blocking estrogen can slow the cancer’s return or progression.
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
This trial tests whether a maintenance treatment (fluzoparil and apatinib) can help keep ovarian cancer from coming back after successful platinum-based chemotherapy. It is for women whose cancer either came back within 6 months of their last treatment (platinum-resistant) or more than 6 months later (platinum-sensitive) and who have responded to further chemo.
Hear when a new Carcinoma, Ovarian Epithelial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.